Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
This protein carries a human IgG1 Fc tag at the C-terminus
The protein has a calculated MW of 80.6 kDa. The protein migrates as 100-150 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Human M-CSF R Protein, Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
Immobilized Human M-CSF Protein, His Tag (Cat. No. MCF-H5247) at 5 μg/mL (100 μL/well) can bind Human M-CSF R Protein, Fc Tag (Cat. No. CSR-H5258) with a linear range of 0.1-4 ng/mL (QC tested).
Immobilized Human M-CSF R Protein, Fc Tag (Cat. No. CSR-H5258) at 5 μg/mL (100 μL/well) can bind Biotinylated Human IL-34 Protein, His,Avitag (Cat. No. IL4-H82E5) with a linear range of 0.2-10 ng/mL (Routinely tested).
Human M-CSF Protein, His Tag (Cat. No. MCF-H5247) captured on CM5 Chip via anti-His antibody can bind Human M-CSF R Protein, Fc Tag (Cat. No. CSR-H5258) with an affinity constant of 1.9 nM as determined in SPR assay (Biacore T200) (Routinely tested).
Loaded Biotinylated Human M-CSF Protein, His,Avitag (Cat. No. MCF-H82E6) on SA Biosensor, can bind Human M-CSF R Protein, Fc Tag (Cat. No. CSR-H5258) with an affinity constant of 24.5 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Loaded Human M-CSF R Protein, Fc Tag (Cat. No. CSR-H5258) on Protein A Biosensor, can bind Human M-CSF Protein, His Tag (Cat. No. MCF-H5247) with an affinity constant of 0.365 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Emerging VoCs, Omicron, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
CD3 proteins and a collection of for bispecific antibody development which are of high specificity and bioactivities and suitable for immunization, antibody screening.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
The MABSOL biotinylated protein collection includes more than a hundred commonly studied drug targets and biomarker proteins.
Comprehensive cytokines including IL families, growth factors, chemokines, TNFs, etc. These products are HEK293 expressed and nearly in authentic structure, high purity and bioactivity, cell based assay/SPR/BLI verified.
To support preclinical/clinical immunogenicity and PK analysis, ACROBiosystems has developed a series of high-affinity anti-idiotypic antibodies. Our pipeline covers five hot targets including adalimum*b, rituxim*b, cetuxim*b, trastuzum*b, and bevacizum*b.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Mirimostim | P-100; CSF-HU | Approved | Jcr Pharmaceuticals Co Ltd | Costilate, Leukoprol | Japan | Neutropenia | Jcr Pharmaceuticals Co Ltd | 1991-01-01 | Neutropenia | Details |
Nintedanib Esylate | BIBF-1120 | Approved | C.H. Boehringer Sohn Ag & Co. Kg | Ofev, Vargatef | EU | systemic sclerosis-associated interstitial lung disease | Boehringer Ingelheim International Gmbh | 2014-10-15 | Gliosarcoma; Breast Neoplasms; Sarcoma; systemic sclerosis-associated interstitial lung disease; Adenocarcinoma, Clear Cell; Peritoneal Neoplasms; Colorectal Neoplasms; Astrocytoma; Hepatic Insufficiency; Genital Neoplasms, Female; Silicosis; Prostatic Neoplasms; Carcinoma, Squamous Cell; Appendiceal Neoplasms; Fallopian Tube Neoplasms; Leukemia, Myeloid, Acute; Uterine Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Colonic Neoplasms; Ovarian Neoplasms; Telangiectasia, Hereditary Hemorrhagic; Esophageal Neoplasms; Rejection of lung transplantation; Carcinoid Tumor; Endometrial Stromal Tumors; Carcinoma, Renal Cell; Radiation Pneumonitis; Neoplasms; Idiopathic Pulmonary Fibrosis; Solid tumours; Scleroderma, Systemic; Glioblastoma; Small Cell Lung Carcinoma; Mesothelioma; Neuroendocrine Tumors; Pulmonary Fibrosis; Lung Diseases, Interstitial; Multiple Myeloma; Asbestosis; Oligodendroglioma | Details |
Pexidartinib | PLX-3397 | Approved | Daiichi Sankyo Co Ltd | Turalio | United States | Giant Cell Tumor of Tendon Sheath | Daiichi Sankyo Inc | 2019-08-02 | Prostatic Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Melanoma; Leukemia, Myeloid, Acute; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Giant Cell Tumors; Neurofibroma, Plexiform; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Neurofibrosarcoma; Sarcoma; Ovarian Neoplasms; Breast Neoplasms; Arthritis, Rheumatoid; Pancreatic Neoplasms; Glioblastoma; Neoplasms; Hodgkin Disease; Synovitis, Pigmented Villonodular; Squamous Cell Carcinoma of Head and Neck; Leukemia, Promyelocytic, Acute; Giant Cell Tumor of Tendon Sheath; Solid tumours | Details |
Regorafenib | DAST; BAY-73-4506 | Approved | Bayer AG | Stivarga, Resihance | Mainland China | Gastrointestinal Stromal Tumors | Bayer Pharma Ag | 2012-09-27 | Leukemia, Myeloid, Acute; Sarcoma; Gastrinoma; Osteosarcoma; Sarcoma, Ewing; Colorectal Neoplasms; Peritoneal Neoplasms; Gastrointestinal Stromal Tumors; Bile Duct Neoplasms; Fallopian Tube Neoplasms; Esophageal adenocarcinoma; Adenoma; Thyroid Neoplasms; Lung Neoplasms; Thymoma; Carcinoma, Hepatocellular; Adenocarcinoma; Melanoma; Neoplasm Metastasis; Gastrointestinal Neoplasms; Somatostatinoma; Carcinoma, Islet Cell; Ovarian Neoplasms; Liver Neoplasms; Hemangiosarcoma; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Rectal Neoplasms; Carcinoid Tumor; Insulinoma; Solid tumours; Colonic Neoplasms; Neoplasms; Carcinoma, Ovarian Epithelial; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Glioblastoma; Carcinoma, Transitional Cell; Carcinoma, Adenoid Cystic; Glucagonoma | Details |
Pacritinib | SB-1518; ONX-0803 | Approved | Syncore Biotechnology Co Ltd, Concert | VONJO | United States | Primary Myelofibrosis | Cti Biopharma Corp | 2022-02-28 | Lymphoproliferative Disorders; Carcinoma, Non-Small-Cell Lung; Leukemia, Lymphocytic, Chronic, B-Cell; Thrombocythemia, Essential; Leukemia, Myelomonocytic, Juvenile; Lymphoma, T-Cell; Waldenstrom Macroglobulinemia; Thrombocytopenia; Lymphoma, T-Cell, Cutaneous; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Myeloid, Acute; Hepatic Insufficiency; Colorectal Neoplasms; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Primary Myelofibrosis; Coronavirus Infections; Lymphoma, Mantle-Cell; Graft vs Host Disease; Coronavirus Disease 2019 (COVID-19); Leukemia, Myelomonocytic, Chronic; Hodgkin Disease; Myeloproliferative Disorders; Myelodysplastic Syndromes; Polycythemia Vera; Lymphoma, T-Cell, Peripheral; Leukemia; Lymphoma, B-Cell | Details |
Surufatinib | HMPL-012 | Approved | Hutchison Medipharma Ltd | 苏泰达, SULANDA | Mainland China | Neuroendocrine Tumors | Hutchison Medipharma Ltd | 2020-12-29 | Biliary Tract Neoplasms; Hematologic Neoplasms; Solid tumours; Intestinal Neoplasms; Kidney Diseases; Pancreatic neuroendocrine tumors (pNET); Neoplasms; Small Cell Lung Carcinoma; Neuroendocrine Tumors; Sarcoma; Hepatic Insufficiency; Bile Duct Neoplasms; Carcinoma, Neuroendocrine; Thyroid Neoplasms; Appendiceal Neoplasms | Details |
Pazopanib Hydrochloride | GSK-786034; GW-786034B; SB-786034; GW-786034 | Approved | Glaxosmithkline Plc, Novartis Pharma Ag | 维全特, Armala, Votrient, Patorma | Mainland China | Carcinoma, Renal Cell | Novartis Pharma Schweiz Ag | 2009-10-19 | Peritoneal Neoplasms; Lymphoma; Uterine Neoplasms; Lung Neoplasms; Carcinoma, Small Cell; Thyroid Neoplasms; Gastrointestinal Stromal Tumors; Gliosarcoma; Carcinoma, Mucoepidermoid; Genital Neoplasms, Female; Uterine Cervical Diseases; Choriocarcinoma; Colorectal Neoplasms; Neuroblastoma; Osteosarcoma; Gastrinoma; Psoriasis; Brain Neoplasms; Urethral Neoplasms; Breast Neoplasms; Medullary thyroid cancer (MTC); von Hippel-Lindau Disease; Gastrointestinal Neoplasms; Carcinoma, Hepatocellular; Melanoma; Endodermal Sinus Tumor; Neoplasms, Germ Cell and Embryonal; Paraganglioma; Thyroid Cancer, Papillary; Neoplasm Metastasis; Uterine Cervical Neoplasms; Breast Neoplasms, Male; Prostatic Neoplasms; Macular Degeneration; Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms; Leukemia, Myeloid, Acute; Glioma; Germinoma; Carcinoma, Neuroendocrine; Carcinoma, Embryonal; Carcinoma, Squamous Cell; Telangiectasia, Hereditary Hemorrhagic; Thyroid Carcinoma, Anaplastic; Neoplasms; Carcinoid Tumor; Herpes Genitalis; Pheoc | Details |
Sunitinib Malate | PHA-290940; SU-010398; SU-11248; PNU-290940AD; PHA-290940AD; GB-102; PNU-290940; SU-011248-L-malate salt | Approved | Pfizer Pharmaceuticals Ltd (China) | 索坦, Sutent | Japan | Pancreatic neuroendocrine tumors (pNET) | Pfizer Inc | 2006-01-26 | Teratoma; Ovarian Neoplasms; Fibromatosis, Aggressive; Solid tumours; Intestinal Neoplasms; Kidney Neoplasms; Liver Neoplasms; Leiomyosarcoma; Fibrosarcoma; HIV Infections; Head and Neck Neoplasms; Lymphoma, B-Cell, Marginal Zone; Lymphoma, B-Cell; Leukemia, Myeloid, Accelerated Phase; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma, T-Cell, Peripheral; Ependymoma; Carcinoma, Renal Cell; Histiocytoma, Malignant Fibrous; Carcinoma; Hemangioblastoma; Carcinoma, Islet Cell; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Thoracic Neoplasms; Leukemia, Hairy Cell; Abdominal Neoplasms; Esophageal Neoplasms; Polycythemia Vera; Pelvic Neoplasms; Pheochromocytoma; Glioblastoma; Neurofibromatoses; Pancreatic Neoplasms; Pancreatic neuroendocrine tumors (pNET); Salivary Gland Neoplasms; Small Cell Lung Carcinoma; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Carcinoma, Ovarian Epithelial; Carcinoma, Papillary; Neoplasms; I | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
TT-00420/Atezolizumab | Phase 1 Clinical | Gastrointestinal Neoplasms | Details | ||
C-019199 | C019199 | Phase 1 Clinical | Fujian Haixi New Pharmaceutical Co Ltd | Solid tumours | Details |
PMI-04 | Phase 1 Clinical | Nerve Degeneration | Details | ||
AGX-0073 | AGX-0073 | Phase 1 Clinical | Shanghai Aojian Biological Technology Co Ltd | Solid tumours | Details |
JDB-383 | JDB-383 | Phase 1 Clinical | Shanghai Jiabao Yaoyin Pharmaceutical Technology Co Ltd | Giant Cell Tumor of Tendon Sheath | Details |
SYHA-1817 | SYHA-1817 | Phase 1 Clinical | CSPC Pharmaceutical Group Ltd | Biliary Tract Neoplasms; Stomach Neoplasms; Carcinoma, Squamous Cell | Details |
Simmitinib hydrochloride | SOMCL-15-290 | Phase 1 Clinical | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Solid tumours | Details |
Cilmostim | CSF-1 | Phase 3 Clinical | Pfizer Pharmaceuticals Ltd (China) | Presbyopia | Details |
Derazantinib | ARQ-087.2HCl; AQ-14741087; ARQ-087; BAL-087 | Phase 2 Clinical | Arqule Inc | Solid tumours; Biliary Tract Neoplasms; Stomach Neoplasms; Carcinoma, Transitional Cell; Cholangiocarcinoma; Urogenital Neoplasms; Carcinoma, Hepatocellular | Details |
APL-102 | APL-102; CBT-102 | Phase 1 Clinical | Apollomics Inc | Solid tumours | Details |
NMS-03592088 | NMS-P088; NMS-03592088 | Phase 2 Clinical | Nerviano Medical Sciences Srl | Leukemia, Myelomonocytic, Chronic; Leukemia, Myeloid, Acute | Details |
Tinengotinib | TT-00420 | Phase 2 Clinical | TransThera Sciences (Nanjing) Inc | Solid tumours; Biliary Tract Neoplasms; Stomach Neoplasms; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Cholangiocarcinoma; Breast Neoplasms; Prostatic Neoplasms; Sarcoma; Thyroid Neoplasms; Gallbladder Neoplasms | Details |
Edicotinib | JNJ-244; JNJ-527; PRV-6527; JNJ-40346527 | Phase 1 Clinical | Johnson & Johnson | Hodgkin Disease; Arthritis, Rheumatoid; Cognitive Dysfunction; Alzheimer Disease; Leukemia, Myeloid, Acute; Crohn Disease | Details |
Elzovantinib | TPX-0022 | Phase 2 Clinical | Turning Point Therapeutics Inc | Solid tumours; Stomach Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Sotuletinib | BLZ-945 | Phase 2 Clinical | Novartis Pharma Ag, Celgene Corp | Solid tumours; Neoplasms; Amyotrophic Lateral Sclerosis | Details |
Cabiralizumab | FPA-008; ONO-4687; BMS-986227 | Phase 2 Clinical | Five Prime Therapeutics Inc | Giant Cell Tumor of Tendon Sheath; Ovarian Neoplasms; Head and Neck Neoplasms; Solid tumours; Synovitis, Pigmented Villonodular; Carcinoma, Renal Cell; Pancreatic Neoplasms; Neoplasms; Triple Negative Breast Neoplasms; Arthritis, Rheumatoid; Glioma; Carcinoma, Non-Small-Cell Lung | Details |
LY-3022855 | IMC-CS4; LY-3022855 | Phase 2 Clinical | Eli Lilly And Company | Solid tumours; Neoplasms; Pancreatic Neoplasms; Melanoma; Neoplasm Metastasis | Details |
BC-006 | BC-006; BC006 | Phase 1 Clinical | Dragonboat Biopharmaceutical | Giant Cell Tumor of Tendon Sheath; Solid tumours | Details |
Vimseltinib | DCC-3014 | Phase 3 Clinical | Deciphera | Giant Cell Tumor of Tendon Sheath; Synovitis, Pigmented Villonodular; Neoplasms | Details |
Q-702 | Q-702 | Phase 2 Clinical | Qurient Co Ltd | Solid tumours; Liver Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Neoplasms; Neoplasm Metastasis; Uterine Cervical Neoplasms | Details |
AMB-05X | AMB-05X | Phase 2 Clinical | Amgen Inc | Giant Cell Tumor of Tendon Sheath; Synovitis, Pigmented Villonodular; Idiopathic Pulmonary Fibrosis; Testicular Neoplasms | Details |
Recombinant human GM-CSF oncolytic herpes simplex virus type 2 (OH2) | OH-2; BS-001; oHSV-2 | Phase 2 Clinical | Wuhan Binhui Biotechnology Co Ltd | Solid tumours; Head and Neck Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms; Neoplasms; Liver Diseases; Central Nervous System Neoplasms; Urinary Bladder Neoplasms; Digestive System Neoplasms; Sarcoma; Breast Neoplasms; Colorectal Neoplasms; Lymphoma; Lung Neoplasms; Melanoma | Details |
Chiauranib | CS-2164 | Phase 3 Clinical | Shenzhen Chipscreen Biosciences Co Ltd | Ovarian Neoplasms; Solid tumours; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Neoplasms; Sarcoma; Lymphoma, Non-Hodgkin; Carcinoma, Hepatocellular | Details |
HMPL-653 | HMPL-653 | Phase 1 Clinical | Solid tumours; Giant Cell Tumor of Tendon Sheath; Testicular Neoplasms | Details | |
EI-1071 | EI-1071; FB-1071 | Phase 1 Clinical | Elixiron Immunotherapeutics Inc | Giant Cell Tumor of Tendon Sheath; Alzheimer Disease; Nervous System Diseases; Amyotrophic Lateral Sclerosis | Details |
Axatilimab | SNDX-6352; UCB-6352 | Phase 2 Clinical | Ucb, Incyte Corp | Cytokine Release Syndrome; Solid tumours; Graft vs Host Disease; Triple Negative Breast Neoplasms; Neoplasms; Respiratory Distress Syndrome, Adult; Cholangiocarcinoma; Breast Neoplasms; Coronavirus Infections; Neoplasm Metastasis | Details |
Emactuzumab | RG-7155; 6FY6EI1X8R; RO-5509554 | Phase 3 Clinical | F. Hoffmann-La Roche Ltd | Brenner Tumor; Ovarian Neoplasms; Head and Neck Neoplasms; Solid tumours; Carcinoma; Neoplasms; Carcinoma, Transitional Cell; Adenocarcinoma, Clear Cell; Prostatic Neoplasms; Peritoneal Neoplasms; Testicular Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Squamous Cell; Lymphoma, Non-Hodgkin; Adenocarcinoma; Carcinoma, Endometrioid | Details |
ABSK-021 | ABSK-021 | Phase 1 Clinical | ABbisko Therapeutics Co Ltd | Solid tumours; Giant Cell Tumor of Tendon Sheath; Neoplasms; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Graft vs Host Disease; Sarcoma; Lung Neoplasms; Amyotrophic Lateral Sclerosis | Details |
This web search service is supported by Google Inc.